# A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus

> **NCT07405970** · PHASE3 · RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 316 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** MIL62
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07405970
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07405970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07405970, "A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07405970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*